POMDOCTOR regains compliance with Nasdaq bid rule

POMDOCTOR LIMITED, a digital healthcare company listed on Nasdaq under the symbol POM, reports that it has regained compliance with Nasdaq’s minimum bid price requirement of $1.00 per share under Nasdaq Listing Rule 5450(a)(1).

Rhea-AI Filing Summary

POMDOCTOR LIMITED, a digital healthcare company listed on Nasdaq under the symbol POM, reports that it has regained compliance with Nasdaq’s minimum bid price requirement of $1.00 per share under Nasdaq Listing Rule 5450(a)(1). Nasdaq notified the company on July 10, 2026 that the matter is closed after its American Depositary Shares (ADSs) maintained a closing bid price at or above $1.00 for 10 consecutive business days from June 25 to July 9, 2026.

The company had previously received a Nasdaq notice on January 29, 2026 after its ADS closing bid price stayed below $1.00 for 30 consecutive business days. With compliance restored, POMDOCTOR’s ADSs will continue to be listed on Nasdaq, and the company continues to focus on AI-enabled and predictive healthcare solutions.

Filing Explained

POM’s ADS listing remains on Nasdaq after the bid-price deficiency was closed, with compliance confirmed for the required 10-day period.

Form 6-K is a foreign private issuer’s interim report for material information published in its home market, and this July 13, 2026 filing reports that POMDOCTOR received Nasdaq’s July 10, 2026 compliance letter confirming it had regained compliance with the $1.00 minimum bid-price requirement.

The disclosed lifecycle is complete: Nasdaq found closing bid prices at or above $1.00 for 10 consecutive business days from June 25, 2026 through July 9, 2026, closed the matter, and said the ADSs will continue to be listed on Nasdaq under the ticker symbol POM. The filing identifies the matter as following a January 29, 2026 notice that the ADS closing bid price had remained below $1.00 for 30 consecutive business days.

Key Figures

Minimum bid price requirement: $1.00 per share Non-compliance period length: 30 consecutive business days Compliance period length: 10 consecutive business days +2 more

5 metrics

Minimum bid price requirement $1.00 per share Nasdaq Listing Rule 5450(a)(1) minimum bid price threshold

Non-compliance period length 30 consecutive business days ADS closing bid price below $1.00 before January 29, 2026 notice

Compliance period length 10 consecutive business days ADS closing bid price at or above $1.00 from June 25 to July 9, 2026

Compliance letter date July 10, 2026 Date Nasdaq informed company that bid price compliance was regained

Initial Nasdaq notice date January 29, 2026 Date Nasdaq notified company of bid price deficiency

Key Terms

Nasdaq Listing Rule 5450(a)(1), minimum bid price requirement, American Depositary Shares, forward-looking statements, +1 more

5 terms

Nasdaq Listing Rule 5450(a)(1) regulatory

"compliance with the minimum bid price requirement of $1.00 per share under Nasdaq Listing Rule 5450(a)(1)"

Nasdaq Listing Rule 5450(a)(1) is a continued-listing standard that sets a minimum share price companies must maintain to remain listed on the Nasdaq market—commonly a $1.00 per-share threshold. Investors care because falling below that floor can trigger a compliance review and possible delisting, which is like failing a minimum grade and losing access to the public market; delisting can reduce liquidity, visibility and the ability to raise capital.

minimum bid price requirement regulatory

"regained compliance with the minimum bid price requirement of $1.00 per share"

A minimum bid price requirement is a rule that a stock must trade above a set price for a specified period to stay listed on an exchange. It matters to investors because falling below that threshold can trigger warnings or removal from the exchange, which can cut liquidity, reduce visibility, and often lead to sharper declines in share value—think of it like a venue’s minimum dress code that, if not met, can bar a performer from the stage.

American Depositary Shares financial

"the closing bid price of the Company’s American Depositary Shares had been below $1.00 per share"

American depositary shares (ADSs) are a way for investors in the United States to buy shares of foreign companies without dealing with international markets directly. They represent ownership in a foreign company's stock and are traded on U.S. stock exchanges, making it easier for American investors to buy, sell, and own parts of companies from around the world.

forward-looking statements regulatory

"Certain statements in this announcement are forward-looking statements."

Forward-looking statements are predictions or plans that companies share about what they expect to happen in the future, like estimating sales or profits. They matter because they help investors understand a company's outlook, but since they are based on guesses and assumptions, they can sometimes be wrong.

predictive healthcare capabilities medical

"focused on advancing AI-enabled healthcare solutions and expanding predictive healthcare capabilities"

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What did POM (POMDOCTOR LIMITED) announce regarding its Nasdaq listing?

POMDOCTOR LIMITED announced it has regained compliance with Nasdaq’s minimum bid price requirement of $1.00 per share under Listing Rule 5450(a)(1), and its American Depositary Shares will continue to be listed on Nasdaq.

What is the Nasdaq minimum bid price requirement mentioned by POM (POMDOCTOR LIMITED)?

Nasdaq Listing Rule 5450(a)(1) requires a minimum bid price of $1.00 per share. POMDOCTOR LIMITED’s American Depositary Shares met or exceeded this price for 10 consecutive business days, restoring compliance with the rule.

When did POM (POMDOCTOR LIMITED) receive confirmation it was back in compliance with Nasdaq rules?

POMDOCTOR LIMITED received a Compliance Letter on July 10, 2026 from Nasdaq. The letter confirmed the company had regained compliance with the $1.00 minimum bid price requirement, and that the compliance matter had been closed.

What led to Nasdaq’s earlier notice to POM (POMDOCTOR LIMITED) about bid price issues?

On January 29, 2026, POMDOCTOR LIMITED received a Nasdaq notification because the closing bid price of its American Depositary Shares had been below $1.00 per share for 30 consecutive business days, triggering a compliance review process.

Over which period did POM (POMDOCTOR LIMITED) maintain the required bid price to regain compliance?

Nasdaq determined that from June 25, 2026 to July 9, 2026, the closing bid price of POMDOCTOR LIMITED’s American Depositary Shares was $1.00 per share or greater for 10 consecutive business days, satisfying the bid price requirement.

What business focus does POM (POMDOCTOR LIMITED) highlight in this disclosure?

POMDOCTOR LIMITED describes itself as a digital healthcare company focused on AI-enabled healthcare solutions and expanding predictive healthcare capabilities, leveraging physician resources, wearable technologies, artificial intelligence and real-world healthcare data.

AI-generated analysis. How Rhea-AI works. Not financial advice.

Form 6-K: How Foreign Companies Report to the SEC →

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Accepted by SEC EDGAR 07/13/2026 - 08:05 AM EDT Learn about SEC filing dates

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

FORM 6-K

Report of Foreign Private Issuer

Pursuant to Rule 13a-16 or 15d-16

under the Securities Exchange Act of 1934

For the month of July 2026

Commission file number: 001-42749

POMDOCTOR LIMITED

Yongxu Industrial Park
No.19-23 Hejing Road, Dongsha Street
Liwan District, Guangzhou 510000

People’s Republic of China

(Address of principal executive offices)

Indicate by check mark whether the registrant files or will file annual reports under cover of Form 20-F or Form 40-F.

Form 20-F ☒    Form 40-F ☐

EXHIBIT INDEX

Exhibit No.		Description
99.1		Press Release—POMDOCTOR LIMITED Regains Compliance with Nasdaq Bid Price Requirement

1

SIGNATURE

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.

POMDOCTOR LIMITED

/s/ Zhenyang Shi

Zhenyang Shi

Chairman and Chief Executive Officer

Date: July 13, 2026

2

Exhibit 99.1

POMDOCTOR LIMITED Regains Compliance with Nasdaq Bid Price Requirement

GUANGZHOU, China, July 13, 2026 /PRNewswire/ -- POMDOCTOR LIMITED (“Pomdoctor” or the “Company”) (NASDAQ: POM), a digital healthcare company focused on advancing AI-enabled healthcare solutions and predictive healthcare capabilities, today announced that on July 10, 2026, the Company received a letter (the “Compliance Letter”) from The Nasdaq Stock Market LLC (“Nasdaq”) informing the Company that it has regained compliance with the minimum bid price requirement of $1.00 per share under Nasdaq Listing Rule 5450(a)(1). As a result, the matter has been closed.

As previously disclosed, on January 29, 2026, the Company received a notification letter from Nasdaq indicating that the closing bid price of the Company’s American Depositary Shares had been below $1.00 per share for 30 consecutive business days. Nasdaq has since determined that, for the last 10 consecutive business days, from June 25, 2026 to July 9, 2026, the closing bid price of the Company’s American Depositary Shares has been at $1.00 per share or greater. Accordingly, the Company has regained compliance with Nasdaq Listing Rule 5450(a)(1).

With Nasdaq’s confirmation of compliance, Pomdoctor American Depositary Shares will continue to be listed on Nasdaq under the ticker symbol “POM.”

About POMDOCTOR LIMITED

POMDOCTOR LIMITED (NASDAQ: POM) is a digital healthcare company focused on advancing AI-enabled healthcare solutions and expanding predictive healthcare capabilities. The Company leverages physician resources, wearable technologies, artificial intelligence, healthcare payment networks and real-world healthcare data to support more personalized, continuous and data-driven healthcare services. Building upon its established healthcare platform and physician network, POM is pursuing the development of a predictive healthcare data and services infrastructure designed to improve healthcare outcomes and create long-term value for patients, healthcare providers and other ecosystem participants. For more information, please visit the Company’s website: http://ir.7shiliu.com.

Forward-Looking Statements

Certain statements in this announcement are forward-looking statements. These forward-looking statements involve known and unknown risks and uncertainties and are based on the Company’s current expectations and projections about future events that the Company believes may affect its financial condition, results of operations, business strategy and financial needs. Investors can find many (but not all) of these statements by the use of words such as “approximates,” “believes,” “hopes,” “expects,” “anticipates,” “estimates,” “projects,” “intends,” “plans,” “will,” “would,” “should,” “could,” “may” or other similar expressions. The Company undertakes no obligation to update or revise publicly any forward-looking statements to reflect subsequent occurring events or circumstances, or changes in its expectations, except as may be required by law. Although the Company believes that the expectations expressed in these forward-looking statements are reasonable, it cannot assure you that such expectations will turn out to be correct, and the Company cautions investors that actual results may differ materially from the anticipated results and encourages investors to review other factors that may affect its future results in the Company’s filings with the SEC.

For more information, please contact:

POMDOCTOR LIMITED
Investor Relations Department
Email: ir@7lk.com

Ascent Investor Relations LLC
Tina Xiao
Phone: +1-646-932-7242
Email: investors@ascent-ir.com

Filing Exhibits & Attachments

1 document

Press Releases

• EX-99.1 PRESS RELEASE - POMDOCTOR LIMITED REGAINS COMPLIANCE WITH NASDAQ BID PRICE REQUI 6.5 KB